Jump to ContentJump to Main Navigation
Innovation, Path Dependency, and PolicyThe Norwegian Case$
Users without a subscription are not able to see the full content.

Jan Fagerberg, David Mowery, and Bart Verspagen

Print publication date: 2009

Print ISBN-13: 9780199551552

Published to Oxford Scholarship Online: May 2009

DOI: 10.1093/acprof:oso/9780199551552.001.0001

Show Summary Details
Page of

PRINTED FROM OXFORD SCHOLARSHIP ONLINE (www.oxfordscholarship.com). (c) Copyright Oxford University Press, 2019. All Rights Reserved. An individual user may print out a PDF of a single chapter of a monograph in OSO for personal use. date: 19 November 2019

The Biotechnology Industry in Norway: A Marginal Sector or Future Core Activity?

The Biotechnology Industry in Norway: A Marginal Sector or Future Core Activity?

Chapter:
(p.235) 9 The Biotechnology Industry in Norway: A Marginal Sector or Future Core Activity?
Source:
Innovation, Path Dependency, and Policy
Author(s):

Terje Grønning

Publisher:
Oxford University Press
DOI:10.1093/acprof:oso/9780199551552.003.0009

The prevalence of successful biotechnology firms has long been associated with the existence of national or regional agglomerations of the biotechnology firms themselves and partners such as large corporations, universities, research institutes, and venture capital firms. It is, however, acknowledged that such agglomeration trends may be most closely associated with medical biotechnology. This chapter examines ninety-three firms that may be classified as biotechnology-related firms in Norway. While there is indeed a great preoccupation with medical biotechnology in Norway, the survey shows that two other distinct traits are present: a concentration of firms focused on diagnostics and related fields, and a focus on marine biotechnology. In a path dependency perspective, these foci may be explained at least in part by the existence of knowledge bases and market opportunities within chemistry based reagents and fish oils respectively, which were present from the times prior to the advent of modern biotechnology. The chapter contributes to the theories on capabilities of individual firms and agglomeration of different firms and other organizations, and suggests that foci on such niches as those which are prevalent in Norway may function with more disperse geographical distribution patterns as compared to cases described in existing literature.

Keywords:   path dependency, Norway, diagnostics, marine biotechnology, biotechnology firms, agglomerations

Oxford Scholarship Online requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.

Please, subscribe or login to access full text content.

If you think you should have access to this title, please contact your librarian.

To troubleshoot, please check our FAQs , and if you can't find the answer there, please contact us .